The CML Drug Nobody Was Watching

Most biotech moves are noise. This one has a data trail.

On June 11, Enliven Therapeutics (Nasdaq: ELVN) stepped onto the stage at the European Hematology Association Congress in Stockholm and presented updated Phase 1 results for ELVN-001. The stock jumped roughly 15% to around $42.50 that session. More importantly, the FDA has now formally aligned on the Phase 3 dose and patient population. That is a different kind of catalyst than a single data readout.

Here is where I am at on this one.

The Hard Patient Population Problem

ELVN-001 targets chronic myeloid leukemia – specifically the patients who have already burned through available TKI therapies. Not first-line. Not second-line necessarily. These are people who have failed multiple prior treatments. Seventy percent of enrolled patients had received three or more prior unique TKIs. Twenty-three percent had gone through five or more.

That context matters. Hitting a 61% overall major molecular response rate in that population is not a small thing.

As of the March 10, 2026 data cutoff, 161 patients were enrolled across dose levels from 10 to 240 mg daily. Seventy-six percent remained on study at cutoff with a median treatment duration of 35 weeks. At the selected 80 mg once-daily dose – the one the FDA just signed off on – the numbers were the strongest in the trial. Overall MMR hit 61%. Deep molecular response reached 30%. And 48% of evaluable patients hit MMR within just 24 weeks.

In patients who had only received one or two prior TKIs, overall MMR climbed to 67%, with 55% hitting the mark by week 24. The safety picture stayed clean. Only 6% discontinued due to adverse events, and the most serious events were less frequent at 80 mg than at higher doses.

The part people skip: tolerability in this class of drugs has historically been the limiting factor. ELVN-001 appears to be threading that needle so far.

What FDA Alignment Actually Unlocks

Enliven reached formal alignment with the FDA on the 80 mg once-daily dose and on including patients who have received at least one prior TKI in the ENABLE-2 Phase 3 trial. That End-of-Phase 2 meeting is targeted for Q3 2026, with Phase 3 initiation expected in the second half of this year.

Phase 3 is no longer a question mark on the horizon. It is a scheduled event.

What this also does is compress the range of outcomes. The bear case for early-stage biotechs is almost always some version of regulatory surprise or trial design uncertainty. One of those two variables just got removed. That does not mean Phase 3 succeeds – nothing does – but the distribution of possible outcomes shifted.

Cash Position and the Offering

The same day the EHA data dropped, Enliven priced a primary offering at $37.50 per share. The company projects combined proceeds and existing cash will fund operations into 2030. Before the raise, the balance sheet showed approximately $452.4M in cash and short-term investments against only $11.5M in total liabilities – a current ratio north of 40.

Q1 2026 net loss came in at roughly $23.6M, with $20.7M of that allocated to R&D. No product revenue yet, which is expected for a company at this stage. The point is that Enliven is not burning fast and it is not going back to market anytime soon. That is a comfortable position heading into a Phase 3 start.

Slight tangent, but it is relevant: Rick Fair came on as CEO in December 2025 and Scott Garland joined the Board in January 2026. The company framed both moves as building out leadership for the transition into late-stage development and eventual commercialization. You do not recruit that kind of bench unless you believe a Phase 3 readout is on the calendar.

Where Analysts Stand

Guggenheim holds a price target of $80. Stifel is at $60. Mizuho moved from $45 to $62 following the EHA update. All three are pointing toward the same thesis: ELVN-001 has a credible path to becoming a meaningful option in resistant CML, and the current trading range does not fully reflect that possibility.

That is the argument, anyway. Whether it plays out depends heavily on what ENABLE-2 looks like at full enrollment.

Quick Reference: The Key Numbers

• Phase 1 enrollment: 161 patients, 76% still on study at March 2026 cutoff
• 80 mg QD overall MMR: 61% – strongest dose cohort in the trial
• Deep molecular response at 80 mg: 30%
• MMR by week 24 at 80 mg: 48% of evaluable patients
• 1-2 prior TKI cohort overall MMR: 67%, with 55% by week 24
• Adverse event discontinuation rate: 6%
• FDA alignment confirmed: 80 mg QD dose, 2L+ population for ENABLE-2
• Phase 3 start: second half of 2026
• End-of-Phase 2 FDA meeting: Q3 2026
• Pre-offering cash: $452.4M; post-offering runway into 2030
• Q1 2026 R&D spend: $20.7M
• Analyst targets: $60 (Stifel), $62 (Mizuho), $80 (Guggenheim)

The risks have not gone away. No approved product. No revenue. Phase 3 trials fail. CML is a competitive space with entrenched players. If enrollment into ENABLE-2 runs slow or the Q3 FDA meeting produces a design change, the timeline stretches and the thesis weakens.

What is interesting is that this company looks different from most clinical-stage names at this price. The balance sheet is strong, the data has improved with each update, the FDA is engaged rather than uncertain, and the leadership team was rebuilt specifically for what comes next. That combination is not common.

The ENABLE-2 launch date is the next real thing to watch. Everything between now and then is just positioning.